Short answer
NEOGENOMICS INC (NEO) filed its Q2 2026 10-Q quarterly report on Jul 28, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $202M (up 11.2% year over year) with net income of $2M.
Q2 2026 key financials · XBRL
- Revenue
- $202M
- +11.2% YoY · +8.0% QoQ
- Net income
- $2M
- +105.0% YoY · +113.1% QoQ
- Operating margin
- -4.8%
- Gross margin
- 45.6%
Source: XBRL data from the NEOGENOMICS INC (NEO) Q2 2026 10-Q on SEC EDGAR. USD.
NEOGENOMICS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $201.7M, up 11.2% YoY from $181.3M, driven by higher test volume and pricing
- Gross margin 45.6% vs 42.6% YoY
- Clinical testing strongest; non-clinical revenue declined amid pharmaceutical trial trends
- Tariffs creating potential supply-chain challenges and customer-demand uncertainty
- 2026 focus: therapy-selection and MRD adoption, precision-oncology investment, community-market expansion
Risk Factors
- No material risk-factor changes disclosed from the December 31, 2025 Form 10-K
- New 0.75% convertible senior notes due 2032, issued June 22, 2026, creating additional debt obligations
- $25.0 million privately negotiated share repurchase in June 2026, reducing cash resources
- Convertible notes and capped call transactions introduce potential dilution and capital-markets complexity
- Existing 10-K risks remain applicable, including operational, competitive, regulatory, and liquidity exposures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NEOGENOMICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.